Lei Hao, Hu Jiahui, Sun Kaijun, Xu Danyan
Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Heart Fail Rev. 2021 Nov;26(6):1505-1514. doi: 10.1007/s10741-020-09959-3.
Cardiac hypertrophy is a significant risk factor for cardiovascular disease, including heart failure, arrhythmia, and sudden death. Cardiac hypertrophy involves both embryonic gene expression and transcriptional reprogramming, which are tightly regulated by epigenetic mechanisms. An increasing number of studies have demonstrated that epigenetics plays an influential role in the occurrence and development of cardiac hypertrophy. Here, we summarize the latest research progress on epigenetics in cardiac hypertrophy involving DNA methylation, histone modification, and non-coding RNA, to help understand the mechanism of epigenetics in cardiac hypertrophy. The expression of both embryonic and functional genes can be precisely regulated by epigenetic mechanisms during cardiac hypertrophy, providing a substantial number of therapeutic targets. Thus, epigenetic treatment is expected to become a novel therapeutic strategy for cardiac hypertrophy. According to the research performed to date, epigenetic mechanisms associated with cardiac hypertrophy remain far from completely understood. Therefore, epigenetic mechanisms require further exploration to improve the prevention, diagnosis, and treatment of cardiac hypertrophy.
心脏肥大是心血管疾病的一个重要危险因素,包括心力衰竭、心律失常和猝死。心脏肥大涉及胚胎基因表达和转录重编程,这些过程受到表观遗传机制的严格调控。越来越多的研究表明,表观遗传学在心脏肥大的发生和发展中发挥着重要作用。在此,我们总结了表观遗传学在心脏肥大方面的最新研究进展,涉及DNA甲基化、组蛋白修饰和非编码RNA,以帮助理解表观遗传学在心脏肥大中的机制。在心脏肥大过程中,胚胎基因和功能基因的表达均可通过表观遗传机制得到精确调控,这提供了大量的治疗靶点。因此,表观遗传治疗有望成为心脏肥大的一种新型治疗策略。根据迄今为止的研究,与心脏肥大相关的表观遗传机制仍远未被完全理解。因此,需要进一步探索表观遗传机制,以改善心脏肥大的预防、诊断和治疗。